Topical Oxygen and Diabetic Foot Ulcers 2
| ISRCTN | ISRCTN13815433 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13815433 |
| IRAS number | 166923 |
| Secondary identifying numbers | 1.0 19/12/2014, IRAS project ID: 166923 |
- Submission date
- 02/02/2015
- Registration date
- 08/06/2015
- Last edited
- 07/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Many wounds fail to heal because of inadequate oxygen levels. Diabetic foot wounds that fail to heal place their sufferers at risk of amputation. The most widespread method of increasing oxygen delivery to wounds to date has been the use of hyperbaric chambers for wounds where there is poor perfusion. These are expensive and time consuming with potential side effects and complications and their use is not common in Europe. The Natrox™ system is a device designed to overcome a number of problems associated with previous methods of oxygen therapy, by delivering continuous oxygen to the wound bed through a dressing. It consists of a small rechargable battery-powered oxygen concentrator which processes oxygen from air and which because of its size and weight is portable and can be held in place by a lightweight strap. It has a very high level of acceptability with patients. A previous study showed that over an 8-week period there was a reduction of around 50% in the size of some chronic hard to heal diabetic foot wounds. This study will contribute to the understanding of the management of these wounds by reviewing the reductions in wound size achieved using Natrox™ topical oxygen therapy. As well as confirming whether the device is clinically effective, we will also study its costeffectiveness.
Who can participate?
Male and female patients aged 18 or over with a diabetic foot ulcer.
What does the study involve?
Participants that have had diabetic foot ulcers from between 4 week and 6 months are randomly allocated into one of two groups. Those in group 1 (intervention) are treated with the Natrox™ system in addition to conventional diabetic ulcer dressing. Those participants in group 2 (control) are treated with a device that looks identical to the Natrox™ device, but does not work. The dressings are changed every 2-3 days and the patietns are followed up on a weekly or fornightly basis to assess how well they are feeling, pain they are experiencing, their general quality of life and whether they are suffering from any adverse effects. Participants that have had their diabetic foot ulcers for longer than 6 months are all given the Natrox™ treatment and are followed up in the same way as the intervention group.
What are the possible benefits and risks of participating?
The treatment may be effective in aiding wound healing but this has not yet been tested formally. There is a risk that the treatment may be of no benefit.
Where is the study run from?
Hospitals run by 12 NHS trusts in the UK
When is the study starting and how long is it expected to run for?
December 2014 to September 2018
Who is funding the study?
Papworth Hospital NHS Foundation Trust (UK)
Who is the main contact?
Mr Paul Hayes
Contact information
Public
Dept of Vascular Surgery
Addenbrookes Hospital
Cambridge
CB2 0QQ
United Kingdom
Study information
| Study design | Double-blinded randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised cross over trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | A randomised, double-blind, placebo-controlled multi-center trial, examining the effect of Topical Oxygen (Natrox TM) on the rates of healing for chronic Diabetic Foot Ulcers 2 (TODFU-2) |
| Study acronym | TODFU-2 |
| Study objectives | Applying additional topical oxygen to chronic diabetic foot wounds will increase the rate of wound healing after 12 weeks of therapy. |
| Ethics approval(s) | NRES Committee East Midlands - Leicester, 09/01/2015, ref: 15/EM/0021 |
| Health condition(s) or problem(s) studied | Patients with diabetic foot ulcers present for more than 4 weeks |
| Intervention | All subjects who are screened will be divided into two groups. Group 1 – subjects with diabetic foot ulcers between 4 weeks and 6 months Subjects are blinded into two arms – active treatment and placebo. The active treatment arm receives the actual Natrox device by having it applied over the surface of the wound, in addition to conventional diabetic ulcer dressing. The placebo arm receives a device that looks identical but is non-functional, and has it applied to the ulcer in the same manner, again in addition to conventional dressing. The dressings are changed every 2-3 days and followed up on a weekly or fortnightly basis over 12 weeks, to assess healing, pain, quality of life and any adverse events. Unblinding occurs if the ulcer has healed less than 20% of the baseline wound size, and given the option to cross over to the treatment arm if they were receiving the placebo, or to withdraw from the study. These patients, including those that heal greater than 20%, are followed up over another 12 weeks or until the ulcer heals. Group 2 – subjects with diabetic foot ulcers greater than 6 months Subjects are all given the active treatment and followed up as per the treatment arm of group 1 |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | Reduction in wound size at 12 weeks relative to the baseline measurement |
| Secondary outcome measures | 1. Absolute closure numbers during the 24-week follow-up period 2. Wound closure rate on a per protocol basis during the 24-week follow-up period 3. Number of infective episodes during the 24-week follow-up period 4. Number of dressing episodes during the 24-week follow-up period 5. Days of hospital treatment as a result of DFU complications after date of randomisation (extra data collection if hospitalised) during the 24-week follow-up period 6. QoL (diabetic foot ulcer scale) at the baseline visit and visits 1 to 8, 10, 12 and 14, and at the 24-week follow-up visit 7. Pain as reported by a visual analogue score at the baseline visit and visits 1 to 8, 10, 12 and 14, and 24-week follow-up |
| Overall study start date | 08/12/2014 |
| Completion date | 30/09/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 140 |
| Key inclusion criteria | 1. A diabetic foot ulcer greater than 4 weeks and less than 6 months in duration for group 1 and greater than 6 months in duration for group 2 2. Minor amputation sites < 50% healed in 4 weeks (the use of negative pressure wound therapy to optimise wound bed is allowable) 3. 2 weeks of standard of care at the hospital based diabetic foot clinic or in a specialist community diabetic podiatry clinic prior to randomisation or entry into the open registry 4. No planned future revascularisation (endovascular or open surgery) or randomisation within 4 weeks following revascularisation being performed 5. Ongoing active chemical or sharp wound debridement prior to, and during, the application of Natrox™ 6. No limit on level of ischaemia, either high or low. The extent of arterial disease will be documented by angiogram or duplex ultrasound and toe blood pressure. The extent of the disease will be documented using the Bollinger score. 7. The subject is 18 years of age or older 8. The patient is willing to complete >75% of follow-up evaluations required by the study protocol 9. The patient is able to abstain from any other treatment of the ulcer for the duration of the study, which would fall outside the normal standard care for a DFU, unless medically necessary 10. The patient agrees to abstain from enrolment in any other clinical trial for the duration of the study 11. The patient is able to read and understand instructions and give voluntary written informed consent 12. The patient is able and willing to follow the protocol requirements |
| Key exclusion criteria | 1. Inability to comply with dressing regime or manage the Natrox™ device 2. Absolute need for a total contact cast 3. Disseminated malignancy 4. Subjects with a life expectancy <1 year 5. Subjects with an ulcer which is <0.5 cm2 or >50 cm2 6. Subject who is dialysis dependent 7. The subject has an invasive soft tissue infection at the time of baseline assessment, requiring oral or intravenous antibiotic therapy 8. Exposed bone without soft tissue or granulation tissue across the surface 9. Acute osteomyelitis (stable, chronic osteomyelitis is allowable, including those maintained on oral antibiotics, as long as there is no planned surgical intervention) 10. Subject being treated with immunosuppressive medication greater than 7.5 mg prednisolone daily 11. Pregnant/lactating females (self‐reported or tested, per institutional requirements) 12. Glycated haemoglobin HbA1C of >12mmol mol1 13. Subjects who have evidence of connective tissue disorders (e.g., vasculitis or rheumatoid arthritis) under active treatment 14. The subject is unable to follow the protocol 15. The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety 16. The patient is a vulnerable or protected adult 17. The patient is unable to provide consent 18. DFU connected to a sinus wound 19. Wounds were it is felt clinically necessary to cover the surface in gel or creams that would prevent the transmission of oxygen to the wounds surface |
| Date of first enrolment | 01/03/2015 |
| Date of final enrolment | 01/08/2015 |
Locations
Countries of recruitment
- England
- Scotland
- United Kingdom
Study participating centres
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
Sponsor information
Industry
Butts Business Centre
Royston
SG8 7SL
United Kingdom
| Website | http://www.inotecamd.com/contact-us |
|---|
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | 31/12/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | The data will be analysed once the trial is complete, and this is likely to be in Feb 2016. The plan is to produce at least 3 papers, one on the clinical impact of the RCT, one on the associated registry, and a final one on the potential cost-effectiveness of the intervention. The journals will be chosen according to the potential impact of the results. We also plan to present the data at national and international meetings, if accepted for presentation or poster sessions. Updated 07/01/2019: Peer-reviewed papers will be published separately for the Group 1 and Group 2 studies. A paper on the Group 2 results is currently under preparation. Analysis of the much more complex Group 1 data has commenced, with submission for publication envisaged during 2019. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available. The study results comprise, for each of the two Groups separately, multiple large datasets covering patient parameters, responses to treatment, and (for Group 1) randomisation details. The core datasets are libraries of photographs, which poses additional privacy concerns. These datasets will be maintained and archived in digital form, together with a paper-based Trial Master File, by the sponsor, Inotec AMD Limited. In addition, individual study sites will each archive their source data and study records in defined archiving facilities. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Abstract results | preliminary results in conference proceedings | 01/09/2017 | No | No | |
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
07/01/2019: Publication and dissemination plan updated and IPD sharing statement added.
05/12/2018: The overall trial end date was changed from 07/12/2015 to 30/09/2018.
09/03/2018: Publication reference added.
26/01/2018: No publications found, verifying study status with principal investigator.
